Evidence map›Paper›PMID 24989696›Full record

ArticleCancer2014

Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Prasad S Adusumilli

Registry-linked trialAbstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02649829 (First-line Immunotherapy Using Wilms' Tumor Protein 1), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02649829 phase1 / phase2completednot on this mapstarted 2017, after this paper: background citation

First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma

TypeinterventionalSponsorUniversity Hospital, AntwerpRan2017 to 2025Enrolled28ConditionsMalignant Pleural MesotheliomaArmsdendritic cell vaccination plus chemotherapy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York.

Funding

Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI RIVIERI, ISABELLE · 2000 to 2015
$29.9M
Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Validation of a risk model for stage I lung adenocarcinomaR21CA164568 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., PATNAIK, SANTOSH KUMAR · 2012 to 2013
$432k
Mesothelin as a biomarker for clinical management of esophageal adenocarcinomaR21CA164585 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., RIZK, NABIL · 2012 to 2013
$426k
NCI NIH HHS P50 CA086438NCI NIH HHS P50 CA086438-13NCI NIH HHS R21 CA164568NCI NIH HHS R21 CA164568-01A1NCI NIH HHS R21 CA164585NCI NIH HHS R21 CA164585-01A1NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsFemaleGlutamatesGuanineHumansLung NeoplasmsMaleMesotheliomaMesothelioma, MalignantPemetrexedPleural NeoplasmsAntibodies, MonoclonalGlutamatesGuaninePemetrexedSS1(dsFv)PE38

Identifiers

PMID24989696
PMCPMC4448967

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.